Skip to main content
Loading

Market Outlook: Dealmaking and M&A for 2025

February 11, 2025
Despite an extended period of lower biopharma stock valuations and a start of declining interest rates, M&A totals remain historically low. With a new U.S. government administration taking office, and regulatory uncertainty, how will this affect M&A trends for 2025? ​
Moderator
Joseph Conahan, Partner, Co-Chair, Mergers and Acquisitions Practice - WilmerHale
Speakers
James Antonopoulos, Managing Director, Head of Healthcare Banking - Roth Capital Partners
Alethia Young, Chief Financial Officer - Bicycle Therapeutics
View all 2025 Program
Testimonials

Double Helix


 

Supporting Bank Sponsor


 

Premier Sponsors

Conference Sponsors


 

Sign up for updates

Stay up-to-date on the BIO CEO and Investor Conference via email.

SIGN UP